Oncimmune Holdings (GB:ONC) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Oncimmune Holdings plc, a leader in autoantibody profiling for precision medicine, has secured a new contract valued at US$0.7 million with a Top 10 Global Pharma Company, building upon a previous agreement worth US$1.5 million. The new project, which cements Oncimmune’s status as a preferred supplier, aims to identify biomarkers for a rare immune-related disease using the company’s advanced bead-based system. CEO Martin Gouldstone expresses confidence in meeting fiscal year targets and achieving profitability by FY25.
For further insights into GB:ONC stock, check out TipRanks’ Stock Analysis page.
